Quest Diagnostics Incorporated Stock Price and Value Analysis

Quest Diagnostics Incorporated (NYSE:DGX) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Quest Diagnostics Incorporated to reach your target.

Target type

DGX Free Cash Flow Trend

Free Cash Flow trendline for DGX
Free Cash Flow trendline for Quest Diagnostics Incorporated
CSV

Based on historical returns, we believe that Quest Diagnostics Incorporated can grow its free cash at a rate of about 7%. That's positive!

AdvantagesDisadvantages
  • This company is making money at a decent rate.
  • This company has fluctuating growth.
  • This company is very stable.
  • This company has a low dividend yield.
  • This stock looks overpriced.

Inside the DGX Numbers

DGX Price
(Quest Diagnostics Incorporated stock price per share)
$258.28
[?] DGX Fair Price
(based on intrinsic value)
$207.30
[?] DGX Safety Price (based on a variable margin of safety) $165.84
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 26% higher than other Healthcare stocks
[?] PE Ratio versus Industry 90% lower than other Diagnostics & Research stocks
[?] Cash Yield 2.99%
[?] Free Cash Flow Jitter 30%
[?] Dividend Yield 1.30% (tax impact)
Shares Shorted 3,734,103

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 3,734,103 shares shorted. With 109,448,074 shares available for purchase and an average trading volume over the past 10 trading days of 902,830, it would take at least 4.1 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2007 1022079 708
2008 1022079 847
2009 1022079 798
2010 1022079 917
2011 1022079 702
2012 1022079 1,001
2013 1022079 463
2014 1022079 727
2015 1022079 592
2016 1022079 861
2017 1022079 906
2018 1022079 900
2019 1022079 925
2020 1022079 1,656
2021 1022079 1,862
2022 1022079 1,316
2023 1022079 865
2024 1022079 922
2025 1022079 1,453

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 19 fiscal years from 2007 to 2025 with positive net income, operating cash flow totaled $23,786 million against net income of $15,612 million, or 1.52 times.

In 2025, operating cash flow was 1.90 times net income, compared with 1.81 times for the earliest three years (2007 to 2009).

In 2025, capital expenditures were $527 million, 27.9% of operating cash flow of $1,886 million, which leaves an estimated $1,359 million after capex. Across the 19 years with reported capex, it averaged 24.6% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2007 340 927 219 2.73
2008 581 1,063 213 1.83
2009 729 997 167 1.37
2010 721 1,118 205 1.55
2011 471 895 161 1.90
2012 556 1,187 182 2.13
2013 849 652 231 0.77
2014 556 944 308 1.70
2015 709 821 263 1.16
2016 645 1,116 293 1.73
2017 772 1,175 252 1.52
2018 736 1,200 383 1.63
2019 858 1,243 400 1.45
2020 1,431 2,005 418 1.40
2021 1,995 2,233 403 1.12
2022 946 1,718 404 1.82
2023 854 1,272 408 1.49
2024 871 1,334 425 1.53
2025 992 1,886 527 1.90

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $11,666 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $2,931 million, 25.1% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 10 of those 10 years.

In 10 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $6,538 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends and cash spent repurchasing shares together were $803 million, 55.3% of estimated free cash flow of $1,453 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 861 223 590 813 94.5%
2017 906 247 465 712 78.6%
2018 900 266 322 588 65.3%
2019 925 286 353 639 69.1%
2020 1,656 297 325 622 37.6%
2021 1,862 309 2,199 2,508 134.7%
2022 1,316 305 1,408 1,713 130.1%
2023 865 314 275 589 68.1%
2024 922 331 151 482 52.3%
2025 1,453 353 450 803 55.3%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $6,705 million in 2007 and $11,035 million in 2025, a compound annual growth rate of 2.8% over 18 years.

Revenue rose 11.8% from 2024 to 2025.

Our estimated free cash flow was $1,453 million in 2025, 13.2% of revenue. In 2007 the estimated margin was 10.6%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2007 6,705 708 10.6%
2008 7,249 847 11.7%
2009 7,455 798 10.7%
2010 7,260 917 12.6%
2011 7,392 702 9.5%
2012 7,383 1,001 13.6%
2013 7,146 463 6.5%
2014 7,435 727 9.8%
2015 7,493 592 7.9%
2016 7,214 861 11.9%
2017 7,402 906 12.2%
2018 7,531 900 12.0%
2019 7,726 925 12.0%
2020 9,437 1,656 17.5%
2021 10,788 1,862 17.3%
2022 9,883 1,316 13.3%
2023 9,252 865 9.4%
2024 9,872 922 9.3%
2025 11,035 1,453 13.2%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $420 million against total liabilities of $8,859 million, or 4.7% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 54.6% of total assets in 2025, compared with 56.9% in 2008, a decrease of 2.3 percentage points.

Stockholders equity was $7,206 million in 2025, compared with $3,625 million in 2008, a rise of 98.8%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 10.7% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2008 8,404 254 4,779 3,625
2009 8,564 534 4,552 4,011
2010 8,528 449 4,474 4,054
2011 9,313 165 5,598 3,715
2012 9,284 296 5,098 4,186
2013 8,948 187 4,975 3,973
2014 9,857 192 5,527 4,330
2015 9,962 133 5,179 4,713
2016 10,100 359 5,286 4,660
2017 10,503 137 5,388 4,955
2018 11,003 135 5,582 5,267
2019 12,843 1,192 7,004 5,687
2020 14,026 1,158 7,053 6,809
2021 13,611 872 6,970 6,483
2022 12,837 315 6,753 5,930
2023 14,022 686 7,528 6,342
2024 16,153 549 9,174 6,813
2025 16,225 420 8,859 7,206

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $258.28, our model's value equals that price if free cash flow grows an average of 10.8 percent a year over the 10 projection years. Our model assumes 6.7 percent a year for this stock, so the price implies growth of 10.8 percent, which is above the 6.7 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $851 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $206.62 6.6%
Current price $258.28 10.8%
20 percent above the current price $309.94 14.0%
Our model (stored fair price) $207.30 6.7%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Every one of the 19 fiscal years we have for Quest Diagnostics Incorporated under its current filer shows positive free cash flow.

At $258.28, the price is above our fair value estimate of $207.30 for Quest Diagnostics Incorporated.

Average free cash flow over the last three years of data was $1,080 million, and across the first three years it was $784 million; over the period it rose sharply.

Year-to-year variability in free cash flow is uneven, measured at 30%.

Quest Diagnostics Incorporated yields 1.30% in dividends.

Our value investing guide explains how to test these numbers against the filings themselves.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 26% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 90% below the average for stocks in the Diagnostics & Research industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Diagnostics & Research industry, the ones closest in market capitalization to Quest Diagnostics Incorporated, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Quest Diagnostics Incorporated (DGX) 28,416 25.7 1.3% 3.0% 25% above
Incyte Corporation (INCY) 23,364 58.5 - 0.6% 166% above
Medpace Holdings (MEDP) 17,078 33.9 - - 3621% above
IQVIA Holdings (IQV) 40,511 29.9 - - 523% above
Charles River Laboratories International (CRL) 15,061 341.7 - 2.1% 70% above
Lantheus Holdings (LNTH) 6,677 25.4 - - 513% above
RadNet (RDNT) 5,491 - - 1.4% 42% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1022079.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: DGX annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in DGX

Does Quest Diagnostics Incorporated have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: DGX

This example shows how we apply the Trendshare checklist to DGX: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 258.28
    • Market cap: $28B
    • EPS: 10.04
  2. Step 2 — Valuation checks

    • P/E: 25.725
    • FCF yield: 3.0%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.